Fractional third and fourth dose of RTS,S/AS01 malaria candidate vaccine: A phase 2a controlled human malaria parasite infection and immunogenicity study

Journal of Infectious Diseases

Volumn 214, Issue 5, 2016, Pages 762-771

  Regules, Jason A ^a,c,f   Cicatelli, Susan B ^d   Bennett, Jason W ^a,c,f   Paolino, Kristopher M ^d   Twomey, Patrick S ^b,c   Moon, James E ^a,c   Kathcart, April K ^a,c   Hauns, Kevin D ^a,c   Komisar, Jack L ^a,c   Qabar, Aziz N ^a,c   Davidson, Silas A ^e   Dutta, Sheetij ^a,c   Griffith, Matthew E ^f   Magee, Charles D ^f   Wojnarski, Mariusz ^b,c   Livezey, Jeffrey R ^b,c   Kress, Adrian T ^b,c   Waterman, Paige E ^d   Jongert, Erik ⁱ   Wille Reece, Ulrike ^g   Volkmuth, Wayne ^h   Emerling, Daniel ^h   Robinson, William H ^h   Lievens, Marc ⁱ   Morelle, Danielle ⁱ   Lee, Cynthia K ^g   Yassin Rajkumar, Bebi ^g   Weltzin, Richard ^g   Cohen, Joe ⁱ   Paris, Robert M ^c   Waters, Norman C ^a,c   Birkett, Ashley J ⁱ   Kaslow, David C ⁱ   Ballou, W Ripley ⁱ   Ockenhouse, Christian F ^g   Vekemans, Johan ⁱ   more..

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b Experimental Therapeutics Branch   (United States)

^c Military Malaria Research Program   (United States)

^d Clinical Trials Center   (United States)

^e WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^f UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^g PATH   (United States)

^h Atreca Inc   (United States)

ⁱ GSK   (Belgium)

Author keywords

Controlled human malaria parasite infection; Delayed fractional dose; Efficacy; Immunogenicity; Malaria; Plasmodium falciparum; RTS S AS01; Safety; Vaccine spacing

Indexed keywords

CHLOROQUINE; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; MALARIA VACCINE; MESSENGER RNA; PROTOZOON ANTIBODY; RECOMBINANT VACCINE; RTS,S-AS01 VACCINE;

ADULT; ANOPHELES STEPHENSI; ANTIGEN BINDING; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED HUMAN MALARIA PARASITE INFECTION; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MALARIA; MALARIA CONTROL; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PARASITEMIA; PHASE 2 CLINICAL TRIAL; PLASMABLAST; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; RNA SEQUENCE; TREATMENT DURATION; UNITED STATES; ADOLESCENT; ANTIBODY AFFINITY; BIOSYNTHESIS; CLINICAL TRIAL; IMMUNOLOGY; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, PROTOZOAN; ANTIBODY AFFINITY; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; MALARIA; MALARIA VACCINES; MALE; MIDDLE AGED; VACCINES, SYNTHETIC; YOUNG ADULT;

EID: 84988922610     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw237     Document Type: Article

References (29)

1. WHO world malaria report 2015. http://www.who.int/malaria/publications/world-malaria-report-2015/report/en/. Accessed 16 December 2015.
2. WHO's 68 World Health Assembly 2015. Malaria: draft global technical strategy. Report A68/28, 2015. http://apps.who.int/gb/ebwha/pdf-files/WHA68/A68-28-en.pdf?ua=1. Accessed 21 June 2016.
3. Steketee RW, Campbell CC. Impact of national malaria control scale-up programmes in Africa: magnitude and attribution of effects. Malar J 2010; 9:299.
4. WHO Malaria Vaccine Funders Group. Malaria vaccine technology roadmap, 2013. http://www.who.int/immunization/topics/malaria/vaccine-roadmap/TRM-update-nov13.pdf?ua=1. Accessed 21 June 2016.
5. The RTS,S Clinical Trials Partnership. First results of a phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 2011; 365:1863-75.
6. European Medicines Agency, Science Medicines Health. EMA/CHMP/488348/2015; 24 July 2015. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/news/2015/07/news-detail-002376.jsp&mid=WC0b01ac058004d5c1. Accessed 15 October 2015.
7. Ockenhouse CF, Regules J, Tosh D, et al. Ad35.CS.01-RTS,S/AS01 heterologous prime boost vaccine efficacy against sporozoite challenge in healthy malarianaïve adults. PLoS One 2015; 10:e0131571.
8. Stoute JA, Slaoui M, Heppner DG, et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N Engl J Med 1997; 336:86-91.
9. Cohen J, Nussenzweig V, Nussenzweig R, Vekemans J, Leach A. From the circumsporozoite protein to the RTS, S/AS candidate vaccine. Hum Vacc 2010; 6:90-6.
10. Gordon DM, McGovern TW, Krzych U, et al. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J Infect Dis 1995; 171:1576-85.
11. Kamau E, Tolbert LS, Kortepeter L, et al. Development of a highly sensitive genusspecific quantitative reverse transcriptase real-time PCR assay for detection and quantitation of plasmodium by amplifying RNA and DNA of the 18S rRNA genes. J Clin Microbiol 2011; 49:2946-53.
12. Clement F, Dewar V, Van Braeckel E, et al. Validation of an enzyme-linked immunosorbent assay for the quantification of human IgG directed against the repeat region of the circumsporozoite protein of the parasite Plasmodium falciparum. Malar J 2012; 11:384.
13. Tan YC, Blum LK, Kongpachith S, et al. High-throughput sequencing of natively paired antibody chains provides evidence for original antigenic sin shaping the antibody response to influenza vaccination. Clin Immunol 2014; 151:55-65.
14. Volpe JM, Cowell LG, Kepler TB. SoDA: implementation of a 3D alignment algorithm for inference of antigen receptor recombinations. Bioinformatics 2006; 22:438-44.
15. >+< T cell responses and protection against Plasmodium falciparum infection. PLoS One 2013; 8:e61395.
16. RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 2015; 386:31-45.
17. Halbroth BR, Draper SJ. Recent developments in malaria vaccinology. Adv Parasitol 2015; 88:1-49.
18. Shlomchik MJ, Weisel F. Germinal center selection and the development of memory B and plasma cells. Immunol Rev 2012; 247:52-63.
19. Lambert PH, Liu M, Siegrist CA. Can successful vaccines teach us how to induce efficient protective immune responses? Nat Med 2005; 11:S54-62.
20. Bosnak M, Dikici B, Bosnak V, Haspolat K. Accelerated hepatitis B vaccination schedule in childhood. Pediatr Int 2002; 44:663-5.
21. Whitney CG, Goldblatt D, O'Brien KL. Dosing schedules for pneumococcal conjugate vaccine: considerations for policy makers. Pediatr Infect Dis J 2014; 33 (pl 2):S172-81.
22. Malerczyk C, Vakil HB, BenderW. Rabies pre-exposure vaccination of children with purified chick embryo cell vaccine (PCECV). Hum Vaccin Immunother 2013; 9:1454-9.
23. Kester KE, Cummings JF, Ockenhouse CF, et al. RTS,S Malaria Vaccine Evaluation Group. Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research. Vaccine 2008; 26:2191-202.
24. Asante KP, Abdulla S, Agnandji S, et al. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. Lancet Infect Dis 2011; 11:741-9.
25. Obaro SK, Ota MO. Sense and the science of childhood immunization: can we achieve more with less? Vaccine 2006; 24:6460-7.
26. Guerin PJ, Naess LM, Fogg C, et al. Immunogenicity of fractional doses of tetravalent a/c/y/w135 meningococcal polysaccharide vaccine: results from a randomized non-inferiority controlled trial in Uganda. PLoS Negl Trop Dis 2008; 2: e342.
27. Resik S, Tejeda A, Sutter RW, et al. Priming after a fractional dose of inactivated poliovirus vaccine. New Engl J Med 2013; 368:416-24.
28. Hoffman SL, Vekemans J, Richie TL, Duffy PE. The march toward malaria vaccines. Vaccine 2015; 33(pl 4):D13-23.
29. WHO preferred product characteristics (PPC) for malaria vaccines, 2014. http://apps.who.int/iris/bitstream/10665/149822/1/WHO-IVB-14.09-eng.pdf. Accessed 10 October 2015.